Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
78.13M
Enterprise Value
1.82M
Income
-11.83M
Sales
25.13M
Book/sh
4.84
Cash/sh
5.37
Employees
93
IPO
Aug 11, 2009
P/E
-
Forward P/E
-
PEG
-
P/S
3.11
P/B
1.08
P/C
0.97
P/FCF
-
EV/EBITDA
-
EV/Sales
0.07
Quick Ratio
3.04
Current Ratio
3.05
Debt/Eq
0.06
LT Debt/Eq
0.06
Option/Short
Yes / Yes
EPS (ttm)
-0.79
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
20.68% 2.82%
Sales past 3/5Y
1.95% 3.52%
EPS Y/Y TTM
-241.27%
Sales Y/Y TTM
-39.11%
EPS Q/Q
-46.49%
Sales Q/Q
-74.00%
Insider Own
41.60%
Insider Trans
0.00%
Inst Own
21.29%
Inst Trans
-5.11%
ROA
-9.94%
ROE
-18.11%
ROIC
-15.44%
Gross Margin
82.39%
Oper. Margin
-36.72%
Profit Margin
-47.05%
SMA20
-8.61%
SMA50
-21.13%
SMA200
6.02%
Trades
Shs Outstand
14.99M
Shs Float
8.75M
52W High
9.28 -43.86%
52W Low
1.43 263.17%
Volatility
19.05% 17.57%
ATR (14)
0.81
RSI (14)
44.15
Beta
0.28
Rel Volume
0.00
Avg Volume
110.58K
Volume
0
Perf Week
-2.98%
Perf Month
-27.44%
Perf Quarter
-31.72%
Perf Half Y
31.22%
Perf YTD
68.81%
Perf Year
218.42%
Perf 3Y
319.92%
Perf 5Y
158.41%
Perf 10Y
25.82%
Prev Close
5.21
Price
5.21
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$9.75
Implied Upside
+87.1%
Analysts3incl. previous ratings
Rating Distribution1 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 12, 2012Reiterated
UBS logoUUBS
Neutral$6.50 → $5-4.0%
Feb 01, 2011Reiterated
UBS logoUUBS
Neutral$8 → $6.50+24.8%
Dec 16, 2010Downgrade
UBS logoUUBS
Buy → Neutral$10 → $8+53.6%
Aug 17, 2010Reiterated
UBS logoUUBS
Buy$11 → $10+91.9%
Aug 17, 2010Reiterated
MMorgan Joseph
Buy$15 → $10+91.9%
Aug 17, 2010Downgrade
JEF logoJJefferies
Buy → Hold$13 → $5.50+5.6%
May 14, 2010Reiterated
MMorgan Joseph
Buy$21 → $15+187.9%
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. It operates through the following geographical segments: China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The firm products include Acetadote, Caldolor, Kristalose, Vaprisol, Talicia, Vibativ, Sancuso, Omeclamox, RediTrex, and Other. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.
FounderMr. A. J. Kazimi MBA
Vice President Accounting & Finance and CFOMr. John Michael Hamm C.M.A.
Senior VP of Operations & Chief Compliance OfficerMr. Todd M. Anthony
Managing Director of Banking & Investor RelationsMr. Adam S. Mostafa